Letrozit contains Letrozole. Letrozit uses:
|Therapeutic Class:||Hormonal Chemotherapy|
|Manufacturer:||GENEUX SCIENCE LABORATORIESS|
|Last Updated:||2020-11-19 18:15:00|
Letrozit contains Letrozole 2.5 Mg. Letrozit doses
The recommended dose is one 2.5 mg tablet administered once a day, regardless to meals. In patients with advanced disease, treatment with Letrozit Tablet should be continued until tumor progression is evident. Treatment should be discontinued at tumor relapse. No dose adjustment is required for elderly patients. Patients treated with Letrozit Tablet do not require glucocorticoid or mineralocorticoid replacement therapy.
Letrozit is generally well tolerated. The observed adverse reactions are mild or moderate in nature including hot flashes, night sweats, weight increase, nausea, vaginal bleeding & irritation, endometrial proliferation disorders etc.
Letrozit is a nonsteroidal aromatase inhibitor. It inhibits the conversion of androgen to estrogen. In contrast to ovariectomy, treatment with letrozole does not lead to an increase in serum FSH. Letrozit selectively inhibits gonadal steroidogenesis but has no significant effect on adrenal mineralocorticoid or glucocorticoid synthesis. Letrozit inhibits the aromatase enzyme by competitively binding to the heme of the cytochrome P450 subunit of the enzyme, resulting in a reduction of estrogen biosynthesis in all tissues. Treatment of women with letrozole significantly lowers serum estrone, estradiol and estrone sulfate and has not been shown to significantly affect the adrenal corticosteroid synthesis, ldosterone synthesis, or synthesis of thyroid hormones.
Since fatigue and dizziness have been observed with the use of Letrozit and somnolence was uncommonly reported, caution is advised when driving or using machinery.
A pharmacokinetic interaction study with cimetidine & warfarin showed no clinically significant effect on Letrozit pharmacokinetics. In in-vitro experiments, Letrozit & diazepam showed no significant inhibition in the metabolism of each other. Coadministration of Letrozit and tamoxifen 20 mg daily resulted in a reduction of Letrozit plasma levels of 38% on average. Clinical experience in the second-line breast cancer pivotal trials indicates that the therapeutic effect of Letrozit therapy is not impaired if Letrozit is administered immediately after tamoxifen.
Pregnancy Category D. It is not known if Letrozit is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Letrozit is administered to a nursing woman.
Letrozit may cause fetal harm when administered to a pregnant woman and offers no clinical benefit to premenopausal women with breast cancer. Letrozit is contraindicated in women who are or may become pregnant. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to a fetus.
Renal Impairment: No dosage adjustment is required for patients with renal impairment if creatinine clearance is 10 ml/min.
Hepatic Impairment: No dosage adjustment is recommended for patients with mild to moderate hepatic impairment. The dose of Letrozit in patients with cirrhosis and severe hepatic dysfunction should be reduced by 50%. The recommended dose for such patients is 2.5 mg administered every other day.
Pediatric Use: The safety and effectiveness in pediatric patients have not been established.
Isolated cases of overdosage with Letrozit have been reported. No specific treatment for overdosage is known; treatment should be symptomatic and supportive.
Store in a cool and dry place protected from light and moisture.
Letrozit Tablet price in India 140.25